Safety, strength and simplicity of efavirenz in pregnancy

Southern African Journal of HIV Medicine

Volumn , Issue 43, 2012, Pages 28-33

  Pillay, Prinitha ^a   Black, Vivian ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

BIRTH DEFECT; BREAST FEEDING; CD4 LYMPHOCYTE COUNT; CHILD HEALTH; DRUG ERUPTION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; LIVER TOXICITY; MATERNAL WELFARE; MENINGOMYELOCELE; NEURAL TUBE DEFECT; PATIENT COMPLIANCE; PATIENT SAFETY; PLACENTAL TRANSFER; PREGNANCY; PREGNANT WOMAN; PROPHYLAXIS; REVIEW; SOUTH AFRICA; SURVIVAL TIME;

EID: 84860739748     PISSN: 16089693     EISSN: None     Source Type: Journal    
DOI: 10.4102/sajhivmed.v13i1.157     Document Type: Review

References (48)

1. USAID HIV/AIDS Health Profile Sub Saharan Africa. http://www.usaid.gov/ our-work/global-health/aids/Countries/africa/hiv-summary-africa.pdf (accessed 23 November 2011).
2. UNAIDS WorldAIDSday report-2011-en.pdf. http://www.unaids.org/en/media/ unaids/contentassets/documents/unaidspublication/2011/JC2216-WorldAIDSday- report-2011-en.pdf (accessed 23 November 2011).
3. National Antenatal Sentinel HIV and SyphilisPrevalence Survey in South Africa, 2009. Pretoria: Department of Health, 2010.
4. Black V, Brooke S, Chersich MF. Effect of human immunodeficiency virus treatment on maternal mortality at a tertiary centre in South Africa. Obstet Gynecol 2009;114:292-299.
5. Mid-year Population Estimates 2010. Statistics SA. http://www.statssa. gov.za/publications/P0302/P03022010.pdf (accessed 23 November 2011).
6. Stringer EM, Ekouevl DK, Coetzee D, et al. Coverage of nevirapine-based services to prevent mother-to-child HIV transmission in 4 African countries. JAMA 2010;304(3):293.
7. Clinical guidelines: PMTCT (Prevention of Mother-to-Child Transmission). Pretoria: South African National AIDS Council, 2010.
8. National Strategic Plan for HIV and AIDS, STIs and TB, 2012-2016 Draft Zero 110808 pdf final. http://www.sanac.org.za/files/uploaded/519- NSP%20Draft%20Zero%20110808%20pdf%20%20final.pdf (accessed 23 November 2011).
9. Rapid Advice: use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants, November 2009. Revised June 2010. http://whqlibdoc.who.int/publications/2009/9789241598934-eng.pdf (accessed 23 November 2011).
10. PEPFAR Scientific Advisory Board, Including the HPTN 052 Subcommittee and HPTN 052 Writing Group (Wafaa El Sadr, Myron Cohen, Kevin DeCock, et al.). PEPFAR Scientific Advisory Board Recommendations forthe Office of the US Global AIDS Coordinator:Implications of HPTN 052 for PEPFAR's Treatment Programs 2011. Available from: http://www.pepfar.gov/documents/organization/177126.pdf (accessed 23 November 2011).
11. Mills FJ, Bakanda C, Birungi J, et al. Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: A cohort analysis from Uganda. Ann Intern Med 2011;155(4):209-216.
12. Mugo NR, Heffron R, Donnell D, et al. Increased risk of HIV-1 transmission in pregnancy: A prospective study among African HIV-1 serodiscordant couples. AIDS 2011;25(15):1887-1895.
13. Dorton BJ, Mulindwa J, Li MS, et al. CD4+ cell count and risk for antiretroviral drug resistance among women using peripartum nevirapine for perinatal HIV prevention. BJOG 2011;118(4):495-499.
14. Schouten EJ, Jahn A, Midiani D, et al. Prevention of mother-to-child transmission of HIV and the health-related Millennium Development Goals: time for a public health approach. Lancet 2011;378:282-284.
15. Important Change in SUSTIVA® (efavirenz) Package Insert - Change from Pregnancy Category C to D. http://www.fda.gov/downloads/Safety/MedWatch/ SafetyInformation/SafetyAlertsforHumanMedicalProducts/UCM164871.pdf (accessed 23 November 2011).
16. Ford N, Mofenson L, Kranzer K, et al. Safety of efavirenz in first-trimester of pregnancy: a systematic review and meta-analysis of outcomes from observational cohorts. AIDS 2010;24:1461-1470.
17. Ford N, Calmy A, Mofenson L. Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis. AIDS 2011;25(18):2301-2304.
18. The Antiretroviral Pregnancy Register Interim report 1 January 1989 through 31 January 2011. http://www.apregistry.com/forms/interim-report.pdf (accessed 23 November 2011).
19. March of Dimes Global Report of Birth Defects Wall Chart http://www.marchofdimes.com/downloads/BirthDefectsWallChart.pdf (accessed 23 November 2011).
20. FDA Content and Format for Labeling for Human Prescription Drug and Biological Products - Proposed Rules. Federal Register Vol. 73, No. 104. 2008. http://edocket.access.gpo.gov/2008/pdf/E8-11806.pdf (accessed 23 December 2011).
21. Schwartz SR, Mehta SH, Taha TE, Rees HV, Venter F, Black V. High Pregnancy Intentions and Missed Opportunities for Patient-Provider Communication About Fertility in a South African Cohort of HIV-Positive Women on Antiretroviral Therapy. AIDS and Behavior. 9 June 2011. http://www.springerlink. com/content/e310h87734262755/ (accessed 23 November 2011).
22. Pettifor AE, Rees HV. Young people's sexual health in South Africa: HIV prevalence and sexual behaviours from a nationally representative household survey. AIDS 2005;19:1525-1534. (Pubitemid 41400699)
23. van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004,363(9417):1253-1263. (Pubitemid 38496486)
24. Mbuagbaw LC, Irlam JH, Spaulding A, Rutherford GW, Siegfried N. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals. http://onlinelibrary.wiley.com/doi/10. 1002/14651858.CD004246.pub3/abstract (accessed 25 November 2011).
25. Reiser P, Nassar N, Yazdani B, Armas L, Moreno S. Comparison of efficacy of efavirenz and nevirapine: lessons learned for cohort analysis in light of the 2NN Study. HIV Clin Trials 2003;4(5):358-360. (Pubitemid 37304439)
26. Keiser P, Nassar N, Yazdani B, Armas L, Moreno S. Conference on Retroviruses and Opportunistic Infections (2004: San Francisco). The Use of Observational Databases to Compare Anti-retroviral Effectiveness. Abstract no. 559. http://gateway.nlm.nih.gov/MeetingAbstracts/ma?f=102271521.html (accessed 25 November 2011).
27. Bock P, Fatti G, Grimwood A. Comparing the effectiveness of efavirenz and nevirapine for first-line antiretroviral treatment amongst an adult treatment cohort from South Africa. J Int AIDS Soc 2010;13.P10.
28. Davies M-A, Moultrie H, Eley B, et al. Virologic failure and second-line antiretroviral therapy in children in South Africa - The IeDEA Southern Africa Collaboration. J Acquir Immune Defic Syndr 2011;56:270-278.
29. Nachega JB, Hislop M, Dowdy DW, et al. Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virologlcal outcomes in Southern African adults. AIDS 2008;22:2117-2125.
30. Datay MI, Boulle A, Mant D, Yudkin P. Associations with virologic treatment failure in adults on antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr 2010;54(5):489-495.
31. Tang M, Kanki P, Shafer R. Virological efficacy of the four tenofovir-containing WHO-recommended regimens for initial antiretroviral therapy. IAS 2011 Abstract. http://pag.ias2011.org/abstracts.aspx?aid=2206 (accessed 25 November 2011).
32. Stem JO, Robinson PA, Love J, Lanes S, Imperiale MS, Mayen DL. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV-infected patients. J Acquir Immune Defic Syndr 2003;34:S21-S33. (Pubitemid 37158630)
33. Baylor MS, Johann-Liang R. Hepatotoxicity associated with nevirapine use. J Acquir Immune Defic Syndr 2004;35(5):538-539.
34. Viramune [package insert]. Ridgefield, CT: Boehringer-Ingelheim Pharmaceuticals, 2008.
35. Hitti J, Frenkel LM, Stek AM, et al. Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022. J Aquir Immune Defic Syndr 2004;36(3):772-776. (Pubitemid 38859341)
36. Lyons F, Hopkins S, Kelleher B, et al. Maternal hepatotoxicity with nevirapine as part of combination antiretroviral therapy in pregnancy. HIV Med 2006;7(4):255-260.
37. Jamisse L, Balkus J, Hitti J, et al. Antiretroviral-assodated toxicity among HIV-1-seropositive pregnant women in Mozambique receiving nevirapine-based regimens. J Acquir Immune Defic Syndr 2007;44:371-376. (Pubitemid 46555370)
38. De Lazzari E, León A, Arnaíz JA, et al. Hepatotoxicity of nevirapine in virologically suppressed patients according to gender and CD4 cell counts. HIV Medicine 2008;9(4):221-226. (Pubitemid 351467795)
39. Kesselring AM, Wit FW, Sabin CA, et al. Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy. AIDS 2009;23(13):1689-1699.
40. Ouyang DW, Shapiro DE, Lu M, et al. Increased risk of hepatotoxicity in HIV-infected pregnant women receiving antiretroviral therapy independent of nevirapine exposure. AIDS 2009;23(18):2425-2430.
41. Chu KM, Boulle AM, Ford N, Goemaere E, Asselman V, Van Cutsem G. Nevirapine-associated early hepatotoxicity: Incidence, risk factors, and associated mortality in a primary care ART programme in South Africa. PLoS ONE 2010;5(2):e9183.
42. van Griensven J, Un P, Phe T, Thai S, Lynen L. Substituting nevirapine for efavirenz: risk factors for toxicity in nonnaive patients in a resource-constrained setting. AIDS 2009;23:2374-2376.
43. Kasirye Gitta P, Bakeera-Kitaka S, Kekitiinwa A. Stevens-Johnson syndrome (SJS) following switch to Nevirapine based regimen at Baylor-Uganda's Paediatric Infectious Diseases Clinic, Mulago Hospital. http://www.iasociety. org/Abstracts/A200740712.aspx (accessed 25 November 2011).
44. Mehta U, Maartens G. Is it safe to switch between efavirenz and nevirapine in the event of toxicity? Lancet Infect Dis 2007;7(11):733-738. (Pubitemid 47600092)
45. Campaign for access to essential medicines. Medicins Sans Frontieres. Untangling the Web of Antiretroviral Price Reductions. http://utw.msfaccess.org/ (accessed 23 November 2011).
46. Hsu H, Rydzak C, Cotich K, et al. Quantifying the risks and benefits of efavirenz use in HIV-infected women of childbearing age in the USA. HIV Med 2011;12(2):97-108.
47. Ouattara EN, Anglaret X, Wong AY, et al. Projecting the dinical benefits and risks of using efavirenz-containing ART regimens in women of childbearing age in Sub-Saharan Africa. AIDS 2012;1. [http://dx.doi.org/10.1097/QAD. 0b013e328350fbfb].
48. Fetal alcohol syndrome: dashed hopes, damaged lives. Bull World Health Organ 2011;89:398-399.